MA-EMPATICA/MCROBERTS
Empatica, a pioneer in digital biomarker development and patient monitoring driven by AI, and McRoberts, one of the leaders in ambulatory monitoring of physical activity, announce the integration of all 71 McRoberts endpoints in Empatica’s digital biomarkers portfolio and FDA-cleared platform, bringing its total offering to over 200.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513976022/en/
The FDA-cleared Empatica Health Monitoring Platform will host all 71 McRoberts endpoints, which will be monitored using Empatica's EmbracePlus wearable. With a modular design, it can be worn on the wrist, waist, hip and other locations on the body, providing a range of versatile digital health measures. (Graphic: Business Wire)
The additional digital biomarkers will enhance the Empatica Health Monitoring Platform with new measures in categories including activity monitoring, energy expenditure, and sleep movements, and introduce key Functional Mobility Assessments such as the sit-to-stand test, gait test, timed up & go test, sway test, and stair test, which play a crucial role in assessing physical function and mobility in clinical care and research settings.
“This partnership shows a maturing digital health industry,” said Matteo Lai, Empatica’s CEO and Co-Founder. “Established players are joining forces to provide a one-stop solution to sponsors across the world. You can get the best medical technology and validated measures with a long clinical history in the same place: this means less setup time, costs and patient burden.”
“We are delighted to share the news of our partnership with Empatica,” said Martijn Niessen, CEO at McRoberts. “Combining our mobility analytics with their versatile platform and extensive array of physiological and behavioral biomarkers promises immense benefits for both our customers.”
The partnership cements the Empatica Health Monitoring Platform’s ability to be fully compatible with validated third-party algorithms. It is also the first known instance where an already established provider moves from using their proprietary wearable to a different device platform, allowing them to focus more energies on developing new endpoints. This showcases the confidence placed in Empatica’s technology, particularly in the monitoring capabilities of the EmbracePlus wearable. It also paves the path to additional partnerships, making it a true platform for other digital biomarker developers to have algorithms implemented in large-scale initiatives without needing to worry about the development of dedicated hardware and compatible software.
The McRoberts algorithms are available to all Enterprise plan users of the Empatica Health Monitoring Platform. Visit Empatica’s website to find out more, or reach out directly to Empatica at research@empatica.com.
About Empatica
Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica's FDA-cleared platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. Its flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and the NASA-funded TRISH.
About McRoberts
McRoberts specializes in providing comprehensive solutions for assessing human mobility both in daily life and laboratory settings. McRoberts introduced its first algorithm and wearable sensor system for activity monitoring in 1994. Since then, their MoveMonitor and MoveTest solutions have been extensively utilized in clinical trials, healthcare, and academic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513976022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Blind Sailor Takes the Stage at WEF: "HIRO’s CHOICE" Project to Set Sail13.1.2026 05:00:00 CET | Press release
A Solo, Non-Stop Crossing of the Pacific Ocean “Blind Sailor Single-Handed Pacific Crossing Project 2027” is a world-first initiative in which Mitsuhiro Iwamoto, a completely blind Japanese yachtsman (blind sailor) based in San Diego, will attempt a solo, non-stop trans-Pacific crossing in the spring of 2027. Sailing a 28-foot yacht single-handedly, he aims to cross the Pacific Ocean from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making port. Iwamoto will speak about this project at the World Economic Forum Annual Meeting 2026, to be held in January 2026. Project URL: https://hiros-choice.com/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108087321/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific The message he most wishes to convey at the WEF is the power of choice. He lost his sight at the age of sixteen—a moment when he nearly gave up on
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom